PIK3CA and ovarian carcinoma: One patient with ovarian cancer (PIK3CA E545A mutation) who had received 2 lines of previous chemotherapy achieved PR after 5.3 weeks of treatment at the 40 mg dose level and a CR after 29.3 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, the DoR was 15.2 months.